Clinical trial · Interventional
Aldara for the Treatment of Large and/or Multiple sBCC
Open Study to Evaluate the Efficacy and Tolerance of Imiquimod 5% Cream for the Treatment of a Large and/or Multiple Superficial Basal Cell Carcinoma.
NCT00189280CI-TRIAL-00056657completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
BCC is the most common form of skin cancer. Current treatment is often surgery but this can be limited by the number of lesions, their location the age of the patient or the potential cosmetic outcome. The purpose of this study is to evaluate the effectiveness of imiquimod, on a non surgical treatment, in subjects with multiple of large sBCCs.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Basal Cell | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Imiquimod | Drug | Imiquimod | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- imiqimod 5% cream
- interventionNames
- Drug: Imiquimod
Primary outcomes (1)
- measure
- Clinical clearance of sBCC
- timeFrame
- 12 or 16 weeks after treatment
Secondary outcomes (4)
- measure
- Reduction in size of tumour
- timeFrame
- 12 or 16 weeks after treatment
- measure
- Rate of clearance, Cosmetic outcome
- timeFrame
- 12 or 16 weeks after treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * One or more sBCC on torso, neck or face * Total surface area \<= 40 sq cm Exclusion Criteria: * Pregnancy or women who are breastfeeding * Xeroderma pigmentosum, albinism, epidermodysplasia verruciformis, any genetic anomaly accompanied by skin tumors * Metatypical, adnexal, or sclerodermiform carcinomas * Current or other previous malignant skin tumor (epidermoid carcinoma, melanoma) in the region of the current lesion * Known HIV positive serology * Skin tumor that is already or highly likely to become metastatic * Presence of a clinically significant anomaly or illness (immunological, cardiovascular, pulmonary, hematological, neurological, hepatic, renal, endocrine, gastrointestinal, collagenous) * Previous organ transplant history
References
Publications (0)
Data not yet available
No reference posted for this study.